DGIdb - LINAGLIPTIN Drug Record

LINAGLIPTIN chembl:CHEMBL237500 Approved

Alternate Names:

BI-1356
BI-1356-BS
TRADJENTA
BS-1356-BS
TRAJENTA
BI 1356
BI-1356BS
LINAGLIPTIN
(R)-8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-YNYL-3-METHYL-1-(4-METHYLQUINAZOLIN-2-YLMETHYL)-3,7-DIHYDRO-PURINE-2,6-DIONE
TRADJENTA®
drugbank:08882
pubchem.compound:10096344
chemidplus:668270-12-0
chembl:CHEMBL237500
rxcui:1100699

Drug Info:

Drug Categories	dpp-iv inhibitors
Drug Categories	agents causing angioedema
Drug Categories	blood glucose lowering agents
Drug Categories	cytochrome p-450 cyp3a substrates
Drug Categories	cytochrome p-450 cyp3a4 inhibitors
Drug Categories	cytochrome p-450 cyp3a4 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp3a4 substrates
Drug Categories	cytochrome p-450 cyp3a4 substrates (strength unknown)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	oct1 inhibitors
Drug Categories	oct2 inhibitors
Drug Categories	oct2 substrates
Drug Categories	p-glycoprotein inhibitors
Drug Categories	p-glycoprotein substrates

(2 More Sources)

Publications:

Forst et al., 2012, Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes., Expert Opin Pharmacother
Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos

LINAGLIPTIN POU2F2

Interaction Score: 56.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23073734

Sources:
DTC
LINAGLIPTIN DPP4

Interaction Score: 2.45

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
22149370

Sources:
DrugBank ChemblInteractions GuideToPharmacology TTD

DrugBank: DB08882

Version: 5.1.7

Alternate Names:

LINAGLIPTIN DrugBank Drug Name

668270-12-0 CAS Number

Glyxambi Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing angioedema

Publications:

Forst et al., 2012, Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes., Expert Opin Pharmacother

DTC: LINAGLIPTIN
- Version: 02-September-2020
Alternate Names:

CHEMBL237500 ChEMBL Drug ID

Drug Info:

Publications:

Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos
GuideToPharmacology: 178102936
- Version: 29-September-2020
Alternate Names:

LINAGLIPTIN GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Linagliptin
- Version: 2020.06.01
Alternate Names:

D02EYG TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL237500
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL237500
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Direct Interaction?	True
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

LINAGLIPTIN	DrugBank Drug Name
668270-12-0	CAS Number
Glyxambi	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	agents causing angioedema

LINAGLIPTIN Drug Record

LINAGLIPTIN chembl:CHEMBL237500 Approved

Alternate Names:

Drug Info:

Publications:

LINAGLIPTIN POU2F2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23073734

Sources: DTC

LINAGLIPTIN DPP4

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? True Endogenous Drug? False Specific Action of the Ligand Inhibition

PMIDs: 22149370

Sources: DrugBank ChemblInteractions GuideToPharmacology TTD

DrugBank: DB08882

Alternate Names: LINAGLIPTIN DrugBank Drug Name 668270-12-0 CAS Number Glyxambi Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories agents causing angioedema

Publications: Forst et al., 2012, Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes., Expert Opin Pharmacother

DTC: LINAGLIPTIN

Alternate Names: CHEMBL237500 ChEMBL Drug ID

Drug Info:

Publications: Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos

GuideToPharmacology: 178102936

Alternate Names: LINAGLIPTIN GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Linagliptin

Alternate Names: D02EYG TTD Drug ID

Drug Info:

Publications:

ChemblInteractions: CHEMBL237500

Alternate Names:

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL237500

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
23073734

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? True

Endogenous Drug? False

Specific Action of the Ligand Inhibition

PMIDs:
22149370

Sources:
DrugBank ChemblInteractions GuideToPharmacology TTD

Alternate Names:

LINAGLIPTIN DrugBank Drug Name

668270-12-0 CAS Number

Glyxambi Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents causing angioedema

Publications:

Forst et al., 2012, Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes., Expert Opin Pharmacother

Alternate Names:

CHEMBL237500 ChEMBL Drug ID

Publications:

Ishiguro N et al., 2013, Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods., Drug Metab Dispos

Alternate Names:

LINAGLIPTIN GuideToPharmacology Ligand Name

Alternate Names:

D02EYG TTD Drug ID